Chemically Stapled Peptides That Grab Antibodies Could Replace Large Proteins in Purification and Drug Design | Research

The takeaway

Lactam-stapled peptides derived from Staphylococcus Protein A showed dramatically improved structural stability, protease resistance, and antibody-binding affinity compared to their linear versions, offering a compact alternative for antibody purification.

Markedly enhanced protease resistance
The stapled peptide (s)SpA h1 maintained structural integrity during α-chymotrypsin digestion while its linear counterpart degraded, solving a key limitation of short peptide ligands

What the researchers found

Two peptides (SpA h1 and SpA h2) were designed based on the Fc-binding helices of the Z34C domain from Protein A. Lactam stapling — introducing a chemical bridge between lysine and glutamic acid residues at positions i and i+4 — significantly increased their alpha-helical content as measured by circular dichroism spectroscopy.

The stapled peptides showed markedly improved IgG-binding performance in fluorescence-based capture assays. Surface plasmon resonance confirmed specific, concentration-dependent Fc binding. Critically, (s)SpA h1 demonstrated enhanced resistance to α-chymotrypsin digestion compared to its linear counterpart and showed strong Fc selectivity with minimal Fab binding — properties essential for practical antibody purification and bioconjugation applications.

Why it matters

Antibody-based drugs (biologics) are among the fastest-growing sectors of the pharmaceutical industry, and antibody purification using Protein A chromatography is a bottleneck in manufacturing. Protein A is expensive, large, and can leach into the final product. Small, chemically defined peptides that match its binding ability could reduce costs, improve purity, and enable novel bioconjugation strategies. Lactam stapling addresses the main weakness of short peptides — their tendency to unfold and get degraded — making them practical candidates for industrial and diagnostic use.

How the study worked

The researchers designed two peptide sequences from the Fc-binding helices of the Z34C domain of Staphylococcus aureus Protein A. Lactam staples were introduced by placing lysine and glutamic acid at i, i+4 positions to form intramolecular bridges. Structural characterization used circular dichroism (CD) spectroscopy. Binding was assessed via fluorescence-based IgG capture assays and surface plasmon resonance (SPR). Enzymatic stability was tested using α-chymotrypsin proteolysis assays. Fc versus Fab selectivity was also evaluated.

What this study cannot tell us

The study is at the design and characterization stage — the peptides have not been tested on actual chromatography columns for antibody purification under industrial conditions. Binding affinity values from SPR were not quantified with KD values in the abstract. Only human IgG was tested; performance with other species' antibodies is unknown. Long-term stability under harsh elution conditions (low pH) used in industrial purification was not assessed. Cost and scalability of peptide synthesis with lactam stapling were not addressed.

How to read the evidence

This is a proof-of-concept peptide design and characterization study using established biophysical methods (CD, SPR, proteolysis assays). The results are well-supported for the in vitro setting but have not been validated in applied purification workflows or compared head-to-head with commercial Protein A under equivalent conditions.

When this study was published

Published in 2025, this is a very recent study reflecting the current state of peptide stapling technology and its application to bioprocessing challenges.

The bigger picture

Peptide stapling has emerged as a powerful strategy for stabilizing bioactive peptide conformations, with applications spanning cancer therapy (stapled p53 peptides), infectious disease, and now bioprocessing. This study applies stapling technology to the industrial problem of antibody purification — a multi-billion-dollar market currently dominated by recombinant Protein A resins. If stapled Fc-binding peptides can be produced cheaply and coupled to chromatography media, they could disrupt the antibody manufacturing supply chain while also enabling new diagnostic and bioconjugation technologies.

Questions still open

Can (s)SpA h1 be immobilized on chromatography resins and maintain its binding performance under industrial purification conditions?
How does the binding affinity of the stapled peptides compare quantitatively (KD) to full-length Protein A?
Could this lactam stapling approach be applied to other peptide ligands used in affinity chromatography beyond antibody purification?

Common questions

What is peptide stapling and why does it help?

Peptide stapling is a chemical technique that introduces a bridge (in this case, a lactam bond between lysine and glutamic acid) within a peptide to lock it into its active three-dimensional shape. Short peptides normally flop around in solution and get rapidly chewed up by enzymes. Stapling makes them rigid, stable, and resistant to degradation — essential for practical applications like antibody purification.

Why would you want a peptide alternative to Protein A for antibody purification?

Protein A is a large, expensive bacterial protein used to capture antibodies during drug manufacturing. It can leach into the final product (a safety concern), is costly to produce, and has limited chemical flexibility. Small stapled peptides that bind antibodies just as well could be cheaper to make, easier to customize, and safer — potentially transforming how antibody-based drugs are manufactured.

Read the original research

Enhancement of Structural Stability and IgG Affinity of a Z34C-Derived α-Helical Peptide via Lactam Stapling.

Antibodies (Basel, Switzerland), 14(4)

View on PubMed ↗Publisher’s paper ↗

Citation

Lee, Jung Gu; Lee, Inseo; Kim, Joo-Young; Kim, Suin; Jeong, Woo-Jin; Kim, Ji-Eun. (2025). Enhancement of Structural Stability and IgG Affinity of a Z34C-Derived α-Helical Peptide via Lactam Stapling.. Antibodies (Basel, Switzerland), 14(4). https://doi.org/10.3390/antib14040108